Annovis Bio (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy buntanetap for Alzheimer’s and Parkinson’s diseases, announced that Founder, President and CEO Maria Maccecchini, Ph.D., will participate in two industry conferences in November. The move signals the company’s push to engage with partners and investors as it advances its lead drug candidate through late-stage development.
At U.S. Biotech Day 2026, scheduled for Nov. 16-17 in Philadelphia, Maccecchini will join a panel discussion titled “Bridging the Translational Gap: From Discovery Insights to Clinical Proof” on Nov. 16 from 9:15-9:45 a.m. ET. She will follow with a company presentation from 10:15-10:30 a.m. ET, highlighting Annovis’ clinical programs and upcoming milestones. The presentation comes as the company seeks to differentiate buntanetap, an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action.
Maccecchini will also present at Pharma Partnering Summit 2026, scheduled for Nov. 19-20 in Boston. Her presentation, titled “Restoring Proteostasis in Alzheimer’s and Parkinson’s Diseases with Buntanetap, a Translational Inhibitor of Neurotoxic Proteins,” will take place Nov. 19 from 11:25-11:55 a.m. ET. During both events, she will hold one-on-one meetings with biotechnology and pharmaceutical industry representatives to discuss the company’s clinical progress and potential opportunities.
The conference appearances are significant because they offer Annovis a platform to make its case to potential partners and investors at a time when the company is advancing buntanetap in Phase 3 trials. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. The company is headquartered in Malvern, Pennsylvania, and its progress is closely watched in the neurodegenerative disease space, where treatment options remain limited. For more information, visit www.annovisbio.com and follow the company on LinkedIn, YouTube, and X. The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS. The full press release can be viewed at https://ibn.fm/0D5yA.
The announcement was distributed through MissionIR, a communications platform that is part of the Dynamic Brand Portfolio at IBN. IBN provides wire solutions via InvestorWire, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and corporate communications solutions. For investors, the dual conference schedule offers a window into Annovis’ strategic priorities as it seeks to advance buntanetap and potentially secure partnerships that could shape the therapy’s path to market.
